Exploring predictors of dysphagia in survivors of head and neck cancer: A cross-sectional study.

Support Care Cancer

Biomedical Group (BIO277), Department of Physical Therapy, Health Sciences Faculty, University of Granada, Sport and Health Research Center (IMUDs), Instituto de Investigación Biosanitaria Ibs, Granada, Spain.

Published: February 2024

Purpose: To evaluate the prevalence of dysphagia in survivors of head and neck cancer (sHNC) and to identify the predictors contributing to the development of dysphagia.

Methods: We enrolled 62 sHNC in a cross-sectional study to check the prevalence of dysphagia in sHNC and to evaluate which factors were influencing the presence of this side effect. Besides dysphagia, sociodemographic and clinical characteristics, oral symptoms, maximal mouth opening (MMO), sleep quality and physical condition were evaluated, and a linear regression analysis was performed to verify which of these outcomes impact dysphagia.

Results: Among all the sHNC, 85.5% presented dysphagia. The linear regression analysis confirmed that 44.9% of the variance in dysphagia was determined by coughing, MMO and sleep quality, being MMO the most powerful predictor, followed by coughing and sleep quality.

Conclusion: Dysphagia affected the great majority of sHNC. Moreover, symptoms as coughing, reduced MMO and sleep disorders may act as predictors contributing to the development of dysphagia. Our results emphasize the importance of an early and proper identification of the symptoms as well as an adequate treatment strategy to address the cluster of symptoms that sHNC undergo.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10873441PMC
http://dx.doi.org/10.1007/s00520-024-08358-wDOI Listing

Publication Analysis

Top Keywords

mmo sleep
12
dysphagia
8
dysphagia survivors
8
survivors head
8
head neck
8
neck cancer
8
cross-sectional study
8
prevalence dysphagia
8
predictors contributing
8
contributing development
8

Similar Publications

To compare the effects of home-based rehabilitation and occlusal splints or centre-based rehabilitation in patients with temporomandibular joint disorders (TMD). A systematic review and meta-analysis. PubMed, Embase, Cochrane Library, Web of Science and ClinicalTrials.

View Article and Find Full Text PDF

[Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].

Rev Med Liege

December 2024

Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.

Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which has been developed as once-weekly injection first for the treatment of type 2 diabetes (T2DM), then for the treatment of obesity. Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, semaglutide 1 mg, basal insulin and preprandial boluses of insulin lispro in six studies of the SURPASS programme. In the SURMOUNT programme, tirzepatide showed a marked reduction in body weight, never reached before with a drug, among people with obesity or overweight associated with complications linked to excess weight.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to investigate the effects of lemborexant (LEM) on individuals with insomnia who also experience mild depression or anxiety symptoms.
  • Over a 12-month period, 61 subjects out of 949, who were using medications for depression/anxiety, were evaluated for changes in sleep quality and related measures while being treated with either LEM or a placebo.
  • Results showed that while LEM was effective for improving sleep metrics in the subpopulation, the placebo response was stronger, resulting in a smaller effect size for LEM compared to the overall study population, but no new safety concerns were identified.
View Article and Find Full Text PDF

An exploratory data-driven approach to classify subgroups of patients with temporomandibular disorders based on pain mechanisms.

J Pain

October 2024

Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom. Electronic address:

Article Synopsis
  • Temporomandibular disorders (TMDs) pose treatment challenges due to their complex, non-specific symptoms and are influenced by a mix of biological, psychological, and social factors.
  • An observational study with 102 TMD patients employed network analysis to explore these factors and identify potential subgroups based on pain mechanisms.
  • Results showed two distinct groups: one with nociceptive pain (better responses to manual therapy) and another with nociplastic pain (higher anxiety, depression, and poorer overall health), highlighting the importance of understanding pain mechanisms for personalized treatment approaches.
View Article and Find Full Text PDF

Sleep disturbances associated with pathogenic variants.

J Clin Sleep Med

January 2025

Sleep Institute, Associação Fundo de Incentivo à Pesquisa, São Paulo, Brazil.

Article Synopsis
  • Neurodevelopmental disorders and sleep issues share common genetic risks, with specific variants linked to rare syndromes that report sleep disturbances.
  • The study aimed to identify biological processes affected by these genetic variants by comparing DEAF1 regulatory target genes with insomnia-associated genes.
  • Findings revealed 39 overlapping genes primarily connected to immune processes, cell cycle regulation, and protein degradation, suggesting they may play a role in insomnia among patients with these genetic mutations.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!